Cargando…
ADRB2-Targeting Therapies for Prostate Cancer
There is accumulating evidence that β-2 adrenergic receptor (ADRB2) signaling contributes to the progression and therapy resistance of prostate cancer, whereas availability of clinically tested β-blocker propranolol makes this pathway especially attractive as potential therapeutic target. Yet even i...
Autor principal: | Kulik, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468358/ https://www.ncbi.nlm.nih.gov/pubmed/30871232 http://dx.doi.org/10.3390/cancers11030358 |
Ejemplares similares
-
Genetic Polymorphisms in ADRB2 and ADRB1 Are Associated with Differential Survival in Heart Failure Patients Taking β-Blockers
por: Guerra, Leonardo A., et al.
Publicado: (2022) -
Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network
por: Kulik, George
Publicado: (2015) -
Association of ADRB2 polymorphism with triglyceride levels in Tongans
por: Naka, Izumi, et al.
Publicado: (2013) -
Obesity-related gene ADRB2, ADRB3 and GHRL polymorphisms and the response to a weight loss diet intervention in adult women
por: Saliba, Louise F., et al.
Publicado: (2014) -
Investigating changes in β-adrenergic gene expression (ADRB1 and ADRB2) in Takotsubo (stress) cardiomyopathy syndrome; a pilot study
por: Tutgun Onrat, Serap, et al.
Publicado: (2021)